Search

"Ocular AEs reported during the treatment of AD with dupilumab have been increasing sharply, and were proposed to be under the definition "dupilumab induced ocular surface disease" (DIOSD) by Zirwas et al", commented the authors. Ocular adverse events (AEs) have been increasingly reported after wider use of the monoclonal antibody dupiliumab for the treatment of atopic dermatitis (AD), say authors of a bibliometric analysis published in I Frontiers in Medicine i . A search of the Web of Science database identified 138 articles (or letters) published between 2016 and August 2020 which reported ocular AEs during the treatment of AD with dupilumab. [Extracted from the article]

The risk of gastrointestinal bleeding (GIB) is not increased in patients receiving statins [HMG-CoA reductase inhibitors] alone or with concomitant warfarin, according to findings of a systematic review and meta-analysis published in the I Annals of Pharmacotherapy i . Overall, 48 677 episodes of GIB were reported, including 43 734 in patients who received statins alone and 4943 in patients who received statins with warfarin. [Extracted from the article]

Concomitant use of colchicine and clarithromycin is associated with a potentially life-threatening drug interaction, according to findings of a study published in I Drug Safety i . The potential drug interaction between colchicine and clarithromycin was investigated by searching the US FDA's Adverse Event Reporting System (FAERS) database for case reports in patients eceiving co-administered colchicine and clarithromycin, and searching EMBASE, PubMed and Web of Science databases for articles published between 2015 and 2019 which reported concomitant use of colchicine and clarithromycin. Evidence of Clinically Meaningful Drug-Drug Interaction With Concomitant Use of Colchicine and Clarithromycin. [Extracted from the article]

When safety, efficacy and total costs of treatment and management of adverse events (AEs) are considered, carfilzomib plus dexamethasone appears to be the superior regimen for relapsed or refractory multiple myeloma (RRMM), according to findings of a Bayesian network meta-analysis (NMA) published in I Cancer i . Progression-free survival (PFS), grade 3-4 AEs and the total cost per course (drug costs plus costs for management of AEs) were assessed for each regimen. Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. [Extracted from the article]